- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02310243
Study of Palbociclib in MLL-rearranged Acute Leukemias
Phase Ib/IIa Study of Palbociclib in MLL-rearranged Acute Leukemias AMLSG 23-14/Palbo-AL-1
Diagnosis: Acute myeloid leukemia; Acute lymphoblastic leukemia Age ≥ 18 years, no upper age limit Study drug: Palbociclib Phase Ib/IIa, open-label
- Phase Ib: Based on previous experience with 125 mg palbociclib once daily for 21 days followed by 7 days of rest in patients with breast cancer, liposarcoma, non-small cell lung cancer, hepatocellular carcinoma, ovarian cancer, mantle-cell lymphoma, and glioblastoma, this regimen will be chosen for the first dose to be evaluated in the phase Ib. Based on a 3 + 3 modified Fibonacci design, the tolerable dose of palbociclib for the phase IIa is defined.
- Phase IIa: single-agent palbociclib using the tolerable dose defined in the phase Ib part of the study is administered once daily for 21 days followed by 7 days of rest. Based on the optimal two-stage design of Simon, 21 patients are treated in the first stage. If results are positive, 29 additional patients will be recruited into the second stage of the study. An efficacy of the investigational therapy will be rejected in the first stage of 21 treated patients if two or less patients achieve complete remission (CR), CR with incomplete blood count recovery (CRi), partial remission (PR), or anti-leukemic effect (ALE). If three or more patients achieve CR, CRi, PR, or ALE during this first stage, the trial is intended to be continued in the second stage with a total sample size of 50 patients.
Start of recruitment: July 2015 End of recruitment: July 2017 End of study (last patient out): July 2018 The treatment duration of an individual patient is estimated to be 2-6 months, but may be unlimited in patients with sustained response ("case-by-case decision").
Observation time per patient after entry into the study (incl. treatment) is at least 12 months.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Augsburg, Germany, 86156
- Recruiting
- Klinikum Augsburg
-
Contact:
- Christoph Schmid, MD
- Email: christoph.schmid@klinikum-augsburg.de
-
Bad Saarow, Germany, 15526
- Recruiting
- Helios Klinikum Bad Saarow
-
Contact:
- Daniel Schöndube, MD
- Email: daniel.schoendube@helios-kliniken.de
-
Berlin, Germany, 13353
- Recruiting
- Charité Campus Virchow-Klinikum
-
Contact:
- Jörg Westermann, MD
- Email: joerg.westermann@charite.de
-
Berlin, Germany, 12351
- Recruiting
- Vivantes Klinikum Neukölln
-
Contact:
- Maike de Wit, MD
- Email: maike.dewit@vivantes.de
-
Berlin, Germany, 12200
- Recruiting
- Charite Campus Benjamin Franklin
-
Contact:
- Claudia Bladus, MD
- Email: claudia.baldus@charite.de
-
Bonn, Germany, 53105
- Recruiting
- Universitatsklinikum Bonn
-
Contact:
- Karin Tina Mayer, MD
- Email: karin.mayer@ukb.uni-bonn.de
-
Braunschweig, Germany, 38114
- Recruiting
- Städtisches Klinikum Braunschweig gGmbH
-
Contact:
- Jürgen Krauter, MD
- Email: krauter.juergen@mh-hannover.de
-
Düsseldorf, Germany, 40225
- Recruiting
- Universitätsklinikum Düsseldorf
-
Contact:
- Thomas Schroeder, MD
- Email: thomas.schroeder@med.uni-duesseldorf.de
-
Essen, Germany, 45239
- Recruiting
- Kliniken Essen Süd, Ev. Krankenhaus Essen-Werden gGmbH
-
Contact:
- Mohammed Wattad, MD
- Email: m.wattad@kliniken-essen-sued.de
-
Flensburg, Germany, 24939
- Recruiting
- Malteser Krankenhaus St. Franziskus-Hospital
-
Contact:
- Nadezda Basara, MD
- Email: nadezda.basara@malteser.org
-
Freiburg, Germany, 791016
- Recruiting
- Universitatsklinikum Freiburg
-
Contact:
- Ralph Wäsch, MD
- Email: ralph.waesch@uniklinik-freiburg.de
-
Fulda, Germany, 36043
- Recruiting
- MVZ Osthessen
-
Contact:
- Andrea Distelrath, MD
- Email: distelrath@mvz-osthessen.de
-
Giessen, Germany, 35392
- Recruiting
- Universitätsklinikum Gießen
-
Contact:
- Maisun Abu Samara, MD
- Email: maisun.abu.samra@innere.med.uni-giessen.de
-
Hamburg, Germany, 20246
- Recruiting
- Universitätsklinikum Hamburg-Eppendorf
-
Contact:
- Walter Fiedler, MD
- Email: fiedler@uke.de
-
Hannover, Germany, 30625
- Recruiting
- Medizinische Hochschule Hannover
-
Contact:
- Michael Heuser, MD
- Email: heuser.michael@mh-hannover.de
-
Heidelberg, Germany, 69120
- Recruiting
- Universitätsklinikum Heidelberg
-
Contact:
- Alwin Krämer, MD
- Email: Alwin.Kraemer@med.uni-heidelberg.de
-
Karlsruhe, Germany, 76133
- Recruiting
- Städtisches Klinikum Karlsruhe gGmbH
-
Contact:
- Mark Ringhoffer, MD
- Email: mark.ringhoffer@klinikum-karlsruhe.com
-
Kiel, Germany, 24116
- Recruiting
- Universitätsklinikum Schleswig-Holstein Campus Kiel
-
Contact:
- Heinz-August Horst, MD
- Email: h.horst@med2.uni-kiel.de
-
Lebach, Germany, 66822
- Recruiting
- Caritas-Krankenhaus Lebach
-
Contact:
- Stephan Kremers, MD
- Email: stephankremers@onkologie-lebach.de
-
Magdeburg, Germany, 39120
- Recruiting
- Uni-Klinikum der Otto-von-Guericke-Universität
-
Contact:
- Denise Wolleschak, MD
- Email: denise.wolleschak@med.ovgu.de
-
Mainz, Germany, 55131
- Recruiting
- Universitätsmedizin der Johannes Gutenberg-Universität
-
Contact:
- Thomas Kindler, MD
- Email: thomas.kindler@unimedizin-mainz.de
-
Oldenburg, Germany, 26121
- Recruiting
- Pius Hospital Oldenburg
-
Contact:
- Frank Griesinger, MD
- Email: frank.griesinger@pius-hospital.de
-
Tübingen, Germany, 72076
- Recruiting
- Medizinische Universitätsklinik Tübingen
-
Contact:
- Helmut Salih, MD
- Email: Helmut.Salih@med.uni-tuebingen.de
-
Ulm, Germany, 89081
- Recruiting
- University Hospital of Ulm
-
Contact:
- Peter Paschka, MD
- Phone Number: 45521 0049-731-500
- Email: peter.paschka@uniklinik-ulm.de
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with confirmed diagnosis of acute leukemia with MLL rearrangement according to the 2008 WHO Classification
- Patients with MLL-rearranged leukemia who are refractory to standard induction therapy and not immediate candidates for allogeneic HSCT (bridge to transplant is allowed)
- Patients with MLL-rearranged leukemia who relapsed after standard first-line treatment and are not immediate candidates for allogeneic HSCT (bridge to transplant is allowed)
- Patients with newly diagnosed MLL-rearranged leukemia who are not eligible for intensive first-line therapy
- Genetic/histologic/immunohistologic assessment in one of the central laboratories
- Age ≥ 18 years, no upper age limit
- WHO performance status of ≤ 2
- No prior chemotherapy two weeks before study entry except hydroxyurea to control hyperleukocytosis
- Non-pregnant and non-nursing. Women of child-bearing potential must have a negative serum or urine pregnancy test with a sensitivity of at least 25 mIU/mL within 72 hours prior to registration (WOCBP is defined as a sexually active mature woman who has not undergone a hysterectomy or who has had menses at any time in the preceding 24 months).
- Female patients in the reproductive age and male patients must agree to avoid getting pregnant or to father a child while on therapy and for three months after the last dose of therapy.
- Women of child-bearing potential must either commit to continued abstinence from heterosexual intercourse or begin one acceptable method of birth control (IUD, tubal ligation, or partner's vasectomy). Hormonal contraception is an inadequate method of birth control.
- Men must agree not to father a child and must use a latex condom during any sexual contact with WOCBP while receiving therapy and for three months after therapy is stopped, even if they have undergone successful vasectomy.
- Signed written informed consent
Exclusion Criteria:
- Prior treatment with palbociclib
- Performance status > 2 according to WHO criteria
- Organ insufficiency: creatinine > 1.5 x upper normal serum level; bilirubin, AST, or AP > 2.5 x upper normal serum level; heart failure NYHA III/IV; uncontrolled hypertension; unstable angina; serious cardiac arrhythmia; severe obstructive or restrictive ventilation disorder
- Uncontrolled infection
- Patients with a "currently active" second malignancy other than non-melanoma skin cancer. Patients are not considered to have a "currently active" malignancy if they have completed therapy and are considered by their physician to be at less than 30% risk of relapse within one year.
- Severe neurologic or psychiatric disorder interfering with ability of giving informed consent
- Known or suspected active alcohol or drug abuse
- Known positivity for HIV, active HAV, HBV, or HCV infection
- Bleeding disorder unrelated to leukemia
- Uncontrolled CNS involvement (treatment for CNS-involvement prior to inclusion is allowed)
- QTc > 470 msec (based on the mean value of triplicate ECGs), family or personal history of long or short QT syndrome, Brugada syndrome, or known history of QTc prolongation or Torsade de Pointes
- Uncontrolled electrolyte disorders that can aggravate the effects of a QTc-prolonging drug (e.g., hypocalcemia, hypokalemia, hypomagnesemia)
- No consent for registration, storage, and processing of individual disease characteristics, information on the course of the disease, and information obtained from the family physician and/or other physicians involved in the treatment of the patient about study participation
- No consent for biobanking
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Palbociclib
Phase1b: 125 mg palbociclib once daily for 21 days followed by 7 days of rest; this regimen will be chosen for the first dose to be evaluated. phase IIa: single-agent palbociclib using the tolerable dose defined in the phase Ib part of the study is administered once daily for 21 days followed by 7 days of rest. |
oral, once daily (125mg, 100mg or 75mg) for 21 days
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants with Adverse Events
Time Frame: 12 months
|
Safety assessments
|
12 months
|
Maximum tolerated dose of palbociclib
Time Frame: 12 months
|
12 months
|
|
overall response rate
Time Frame: 12 months
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Overall survival
Time Frame: three years
|
three years
|
Relapse-free survival
Time Frame: three years
|
three years
|
Evaluation of target (CDK6) inhibition by palbociclib
Time Frame: three years
|
three years
|
Assessment of Quality of life
Time Frame: 6 months
|
6 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Leukemia
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Leukemia, Lymphoid
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Protein Kinase Inhibitors
- Palbociclib
Other Study ID Numbers
- AMLSG 23-14
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Myeloid Leukemia
-
University of PennsylvaniaActive, not recruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia, Refractory | Acute Myeloid Leukemia, PediatricUnited States
-
Terrence J Bradley, MDImago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New...RecruitingAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia, in RelapseUnited States
-
Bhavana BhatnagarCTI BioPharmaCompletedRecurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Therapy-Related Acute Myeloid LeukemiaUnited States
-
Washington University School of MedicineWithdrawnRefractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
C. Babis AndreadisGateway for Cancer Research; AVEO Pharmaceuticals, Inc.TerminatedAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
-
Uma BorateNot yet recruitingRecurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia With FLT3/ITD Mutation | Acute Myeloid Leukemia With KMT2A Rearrangement | Acute Myeloid Leukemia With NPM1 MutationUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingAcute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Therapy-Related Acute Myeloid LeukemiaUnited States
-
Kronos BioActive, not recruitingAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States, Spain
-
Massachusetts General HospitalExelixisCompletedRefractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
Clinical Trials on Palbociclib
-
PfizerCompleted
-
PfizerCompleted
-
MegalabsNot yet recruiting
-
PfizerCompletedHealthyUnited States
-
Memorial Sloan Kettering Cancer CenterPfizerCompletedSarcoma | LiposarcomaUnited States
-
PfizerCompleted
-
PfizerCompletedHealthy, Hepatic InsufficiencyUnited States
-
PfizerCompleted